［1］Braunwald E. Diabetes，heart failure，and renal dysfunction: the vicious circles［J］. Prog Cardiovasc Dis，2019，62（4）: 298-302.

［2］Griffin SJ, James KL, Irving GJ. Impact of metformin on cardiovascular disease: a metaanalysis of randomised trials among people with type 2 diabetes［J］. Diabetologia，2017, 60（9）: 1620-1629.

［3］Sano RY, Shinozaki, Ohta T. Sodiumglucose cotransporters: Functional properties and pharmaceutical potential［J］. J Diabetes Investig, 2020, 11（4）: 770-782.

［4］Beitelshees AL，Leslie BR，Taylor SI. Sodiumglucose cotransporter 2 inhibitors: a case study in translational research［J］. Diabetes, 2019, 68（6）: 1109-1120.

［5］Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes［J］. N Engl J Med, 2015, 373（22）: 2117-2128.

［6］McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction［J］. N Engl J Med，2019，381（21）: 1995-2008.

［7］Nassif ME, Windsor SL, Tang F, et al. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINEHF trial［J］. Circulation, 2019, 140（18）: 1463-1476.

［8］Baartscheer A, Schumacher CA, Wüst RCI, et al. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits［J］. Diabetologia, 2017, 60（3）: 568-573.

［9］Uthman L, Baartscheer A, Bleijlevens B, et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation［J］. Diabetologia, 2018, 61（3）: 722-726.

［10］Olgar Y, Tuncay E, Degirmenci S, et al. Ageingassociated increase in SGLT2 disrupts mitochondrial/sarcoplasmic reticulum Ca2+ homeostasis and promotes cardiac dysfunction［J］. J Cell Mol Med，2020，24（15）: 8567-8578.

［11］Lin B, Koibuchi N, Hasegawa Y, et al. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice［J］.Cardiovasc Diabetol, 2014, 13（1）: 1-15.

［12］Kusaka H，Koibuchi N，Hasegawa Y, et al. Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome［J］. Cardiovasc Diabetol，2016，15（1）: 157.

［13］Lee TM，Chang NC，Lin SZ. Dapagliflozin, a selective SGLT2 inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts［J］. Free Radic Biol Med, 2017, 104: 298-310.

［14］Devenny JJ, Godonis HE, Harvey SJ, et al. Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in dietinduced obese （DIO） rats［J］. Obesity, 2012, 20（8）: 1645-1652.

［15］Li CJ，Zhang M，Xue M，et al. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart［J］. Cardiovasc Diabetol, 2019, 18（1）: 15.

［16］Verma S，Rawat S，Ho KL，et al. Empagliflozin increases cardiac energy production in diabetes: novel translational insights into the heart failure benefits of SGLT2 inhibitors［J］. JACC Basic Transl Sci，2018，3（5）: 575-587.

［17］Ye YM, Jia XM, Bajaj M, et al. Dapagliflozin attenuates Na+/H+ exchanger1 in cardiofibroblasts via AMPK activation［J］. Cardiovasc Drugs Ther, 2018, 32（6）: 553-558.

［18］Skogestad J, Aronsen JM, Tovsrud N, et al. Coupling of the Na+/K+ATPase to Ankyrin B controls Na+/Ca2+ exchanger activity in cardiomyocytes［J］. Cardiovasc Res, 2020, 116（1）: 78-90.

［19］Uthman L，Baartscheer A，Bleijlevens B，et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation［J］. Diabetologia，2018，61（3）: 722-726.

［20］Yeves A，Ennis IL. Na+/H+ exchanger and cardiac hypertrophy［J］. Hipertens Riesgo Vasc，2020，37（1）: 22-32.

［21］Habibi J，Aroor AR，Sowers JR，et al. Sodium glucose transporter 2 （SGLT2） inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes［J］. Cardiovasc Diabetol， 2017，16（1）: 9.

［22］Murashige D，Jang C，Neinast M，et al. Comprehensive quantification of fuel use by the failing and nonfailing human heart［J］. Science，2020，370（6514）: 364-368.

［23］Ferrannini E，Mark M，Mayoux E. CV protection in the EMPAREG OUTCOME trial: a “thrifty substrate” hypothesis［J］. Diabetes Care，2016，39（7）: 1108-1114.

［24］Mller N. Ketone body, 3hydroxybutyrate: minor metabolitemajor medical manifestations［J］. J Clin Endocrinol Metab，2020，105（9）: 2884-2892.

［25］Quan N，Li X，Zhang J，et al. Substrate metabolism regulated by Sestrin2mTORC1 alleviates pressure overloadinduced cardiac hypertrophy in aged heart［J］. Redox Biol，2020，36: 101637.

［26］Rahadian A，Fukuda D，Salim HM，et al. Canagliflozin prevents diabetesinduced vascular dysfunction in ApoEdeficient mice［J］. J Atheroscler Thromb，2020，27（11）：1141-1151.

［27］Nakatsu Y，Kokubo H，Bumdelger B，et al. The SGLT2 inhibitor luseogliflozin rapidly normalizes aortic mRNA levels of inflammationrelated but not lipidmetabolismrelated genes and suppresses atherosclerosis in diabetic ApoE KO mice［J］. Int J Mol Sci，2017，18（8）: 1704.

［28］Leng W，Ouyang X，Lei X，et al. The SGLT2 inhibitor dapagliflozin has a therapeutic effect on atherosclerosis in diabetic ApoE-/- mice［J］. Mediators Inflamm，2016，2016：6305735.

［29］AlSharea A，Murphy AJ，Huggins LA，et al. SGLT2 inhibition reduces atherosclerosis by enhancing lipoprotein clearance in Ldlr-/- type 1 diabetic mice［J］. Atherosclerosis，2018，271: 166-176.

［30］Han JH，Oh TJ，Lee G，et al. The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE-/- mice fed a western diet［J］. Diabetologia，2017，60（2）: 364-376.

［31］Aroor AR，Das NA，Carpenter AJ，et al. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness，renal resistivity index and kidney injury［J］. Cardiovasc Diabetol，2018，17（1）: 108.

［32］NasiriAnsari Ν，Dimitriadis GK，Agrogiannis G，et al. Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice［J］. Cardiovasc Diabetol，2018，17（1）: 106.

［33］Gaspari T，Spizzo I，Liu H，et al. Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: a potential mechanism for inhibition of atherogenesis［J］. Diab Vasc Dis Res，2018，15（1）: 64-73.

［34］Mori K，Tsuchiya K，Nakamura S，et al. Ipragliflozininduced adipose expansion inhibits cuffinduced vascular remodeling in mice［J］. Cardiovasc Diabetol, 2019, 18（1）: 83.

［35］Alshnbari AS，Millar SA，O’Sullivan SE，et al. Effect of sodiumglucose cotransporter2 inhibitors on endothelial function: a systematic review of preclinical studies［J］. Diabetes Ther, 2020, 11（9）:1947-1963.

［36］Shigiyama F，Kumashiro N，Miyagi M，et al. Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with earlystage type 2 diabetes mellitus: DEFENCE study［J］. Cardiovasc Diabetol，2017，16（1）: 84.

［37］Sugiyama S，Jinnouchi H，Kurinami N，et al. The SGLT2 inhibitor dapagliflozin significantly improves the peripheral microvascular endothelial function in patients with uncontrolled type 2 diabetes mellitus［J］. Inter Med，2018，15（57）: 2147-2156.

［38］Takahashi H，Nomiyama T，Terawaki Y，et al. Combined treatment with DPP4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice［J］. Biochem Biophys Rep，2019，18: 100640.

［39］Ohgaki R, Wei L, Yamada K，et al. Interaction of the sodium/glucose cotransporter SGLT2 inhibitor canagliflozin with SGLT1 and SGLT2: inhibition kinetics，sidedness of action，and transporterassociated incorporation accounting for its pharmacodynamic and pharmacokinetic features［J］. J Pharmacol Exp Ther, 2016, 358（1）: 94-102.

［40］Sawa Y，Saito M，Ishida N，et al. Pretreatment with KGA2727，a selective SGLT1 inhibitor，is protective against myocardial infarctioninduced ventricular remodeling and heart failure in mice［J］. J Pharmacol Sci，2020，142（1）: 16-25.

［41］Li J，Liu M，Yu H，et al. Mangiferin improves hepatic lipid metabolism mainly through its metabolitenorathyriol by modulating SIRT1/AMPK/SREBP1c signaling［J］. Front Pharmacol，2018，9: 201.

［42］Taylor SI, Blau JE, Rother KI. Possible adverse effects of SGLT2 inhibitors on bone［J］. Lancet Diabetes Endocrinol, 2015, 3（1）: 8-10.